DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition

Theranostics

Volumn 5, Issue 9, 2015, Pages 985-994

  Wu, Xiaoqiu ^a   Zhao, Zilong ^a   Bai, Huarong ^a   Fu, Ting ^a,b   Yang, Chao ^a,c   Hu, Xiaoxiao ^a   Liu, Qiaoling ^a   Champanhac, Carole ^b   Teng, I Ting ^b   Ye, Mao ^a   Tan, Weihong ^a,b  

^a HUNAN UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA   (United States)

^c GANNAN NORMAL UNIVERSITY   (China)

Author keywords

Aptamer; Cell SELEX; Molecular probe; Pancreatic ductal adenocarcinoma

Indexed keywords

APTAMER; UNCLASSIFIED DRUG; XQ 2D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CELL SPECIFICITY; CHEMICAL MODIFICATION; CONCENTRATION (PARAMETERS); CONFOCAL MICROSCOPY; DISSOCIATION CONSTANT; DRUG BINDING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LASER MICROSCOPY; MALE; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PL45 CELL LINE; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, PANCREATIC DUCTAL; FLUORESCENCE IMAGING; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APTAMERS, NUCLEOTIDE; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; HUMANS; MALE; MICE, INBRED BALB C; OPTICAL IMAGING;

EID: 84945914973     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11938     Document Type: Article

References (25)

1. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002; 2: 897-909.
2. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013; 63: 318-48.
3. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011; 378: 607-20.
4. Lee MX, Saif MW. Screening for early pancreatic ductal adenocarcinoma: an urgent call. JOP 2009; 10: 104-8.
5. Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012; 18: 530-8.
6. Folli S, Westermann P, Braichotte D, et al. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res. 1994; 54: 2643-9.
7. Neri D, Carnemolla B, Nissim A, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol. 1997; 15: 1271-5.
8. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem. 1999; 45: 1628-50.
9. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990; 249: 505-10.
10. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818-22.
11. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng. 2007; 24: 381-403.
12. Shangguan DH, Li Y, Tang ZW, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA. 2006; 103: 11838-43.
13. Daniels DA, Chen H, Hicke BJ, et al. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA. 2003; 100: 15416-21.
14. Sefah K, Shangguan DH, Xiong XL, et al. Development of DNA aptamers using Cell-SELEX. Nat Protoc. 2010; 5: 1169-85.
15. Tan WH, Donovan MJ, Jiang JH. Aptamers from cell-based selection for bioanalytical applications. Chem Rev. 2013; 113: 2842-62.
16. Fang XH, Tan WH, Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res. 2010; 43: 48-57.
17. Shangguan DH, Cao ZH, Meng L, et al. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res. 2008; 7: 2133-9.
18. Zhao ZL, Xu L, Shi XL, et al. Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst. 2009; 134: 1808-14.
19. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med. 2006; 47: 668-78.
20. Shi H, He XX, Wang KM, et al. Activatable aptamer probe for contrast-enhanced in vivo cancer imaging based on cell membrane protein-triggered conformation alteration. Proc Natl Acad Sci USA. 2011; 108: 3900-5.
21. Sheng W, Chen T, Kamath R, et al. Aptamer-enabled efficient isolation of cancer cells from whole blood using a microfluidic device. Anal Chem. 2012; 84: 4199-206.
22. Shen Q, Xu L, Zhao LB, et al. Specific capture and release of circulating tumor cells using aptamer-modified nanosubstrates. Adv Mater. 2013; 25: 2368-73.
23. Zhao W, Cui CH, Bose S, et al. Bioinspired multivalent DNA network for capture and release of cells. Proc Natl Acad Sci USA. 2012; 109: 19626-31.
24. Zhu GZ, Zheng J, Song EQ, et al. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA. 2013; 110: 7998-8003.
25. Shangguan DH, Meng L, Cao ZH, et al. Identification of liver cancer-specific aptamers using whole live cells. Anal Chem. 2008; 80: 721-8.